As of close of business last night, Cytokinetics Inc’s stock clocked out at $66.03, down -1.97% from its previous closing price of $67.36. In other words, the price has decreased by -$1.33 from its previous closing price. On the day, 1497892 shares were traded.
Ratios:
To gain a deeper understanding of CYTK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.12 and its Current Ratio is at 6.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.
On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Malik Fady Ibraham sold 32,604 shares for $67.56 per share. The transaction valued at 2,202,606 led to the insider holds 138,973 shares of the business.
HENDERSON JOHN T sold 5,000 shares of CYTK for $382,400 on Feb 14 ’24. The Director now owns 42,632 shares after completing the transaction at $76.48 per share. On Feb 13 ’24, another insider, Blum Robert I, who serves as the President & CEO of the company, sold 12,500 shares for $76.85 each. As a result, the insider received 960,625 and left with 441,797 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6.80B and an Enterprise Value of 6.94B. For the stock, the TTM Price-to-Sale (P/S) ratio is 903.20. Its current Enterprise Value per Revenue stands at 921.96 whereas that against EBITDA is -15.20.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is 76.13, while the 200-Day Moving Average is calculated to be 46.94.
Shares Statistics:
It appears that CYTK traded 4.11M shares on average per day over the past three months and 4.07M shares per day over the past ten days. A total of 101.64M shares are outstanding, with a floating share count of 99.34M. Insiders hold about 3.56% of the company’s shares, while institutions hold 109.61% stake in the company. Shares short for CYTK as of Feb 29, 2024 were 14.53M with a Short Ratio of 3.53, compared to 13.58M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.11% and a Short% of Float of 23.05%.
Earnings Estimates
As of right now, 14 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.14 for the current quarter, with a high estimate of -$0.89 and a low estimate of -$1.36, while EPS last year was -$1.38. The consensus estimate for the next quarter is -$1.12, with high estimates of -$0.82 and low estimates of -$1.38.
Analysts are recommending an EPS of between -$3.43 and -$5.5 for the fiscal current year, implying an average EPS of -$4.45. EPS for the following year is -$3.28, with 14 analysts recommending between -$1.53 and -$5.23.
Revenue Estimates
Based on 15 analysts’ estimates, the company’s revenue will be $145.29M in the next fiscal year. The high estimate is $394.65M and the low estimate is $5M. The average revenue growth estimate for next year is up 2,166.60% from the average revenue estimate for this year.
